AI Not Ready to Cure Cancer
· wellness
The Mirage of AI-Driven Cancer Cures: A Reckoning Overhyped and Underprepared
The notion that artificial intelligence will single-handedly cure cancer has become a tired trope in the tech world, often used to justify grandiose claims. Beneath this hype lies a stark reality: despite significant investment, AI-powered drug discovery remains woefully underprepared for the complexity of human biology.
Vivodyne, a biotech startup, is the latest entrant into this arena with its bold vision for accelerating the path to new cancer treatments using modular robotic labs called HIVE. These machines can grow 20 kinds of human tissue and generate causal biological data – the kind that today’s AI models are missing. CEO Andrei Georgescu claims his team has already achieved twice the throughput of all animal trials in the US, but this may not be enough to overcome the industry’s chronic failures.
The pharmaceutical industry’s dismal track record is a significant obstacle. A staggering 90% of drugs that pass animal testing fail regulatory approval for humans. Even Nobel-prize winning Alphafold, which has made impressive advances in understanding protein structures, has yet to yield a single new drug. Georgescu acknowledges the need for “a sanity check” – recognition that current AI models are inadequate for capturing human biology’s complexity.
Vivodyne’s plan is different: by using real-world human tissue data, they aim to accelerate the path of drug candidates before costly clinical trials. This approach implies no longer flying blind into regulatory purgatory. However, this is not a silver bullet for AI-driven cancer cures. The space requires fundamentally new approaches that can capture causality in human biology.
Studies have shown that generative AI models trained on static snapshots of cells fail to grasp the dynamic relationships between them. Vivodyne’s HIVE machines may provide a crucial step forward by tracking hundreds of thousands of ongoing experiments where diseased tissue is exposed to some stimulus. But will this be enough to overcome the industry’s chronic failures?
Georgescu’s vision for a future of combination therapies targeting multiple pathways is tantalizing, but it remains to be seen whether Vivodyne’s approach can scale. In reality, the answer is not yet clear. We are left with more questions than answers: Can AI-driven cancer cures become more than just a mirage? Will the industry finally reckon with its chronic failures in translating preclinical efficacy into human clinical trials? Only time – and data – will tell.
Reader Views
- TCThe Calm Desk · editorial
The AI cancer cure narrative is stuck in perpetual loop of hype and disappointment. While Vivodyne's approach to using modular robotic labs may seem innovative, its underlying assumption that real-world human tissue data can magically overcome the 90% failure rate of drugs passing animal testing is questionable. We need to acknowledge that the fundamental issue lies not just with AI models but with our understanding of complex biological systems themselves. Can we truly speed up cancer research without fundamentally changing our approach?
- ANAlex N. · habit coach
The article hits on some crucial points about AI's limitations in curing cancer, but let's not forget that the biggest hurdle lies not just in AI itself, but in our understanding of what we're trying to optimize for. We've become so fixated on "accelerating" and "disrupting" the process that we've overlooked a fundamental question: what does it mean to be effective against cancer? Is it solely about throughput or regulatory approvals, or is there a deeper biological imperative at play here? The industry needs to grapple with these philosophical questions before throwing more money and tech at the problem.
- DMDr. Maya O. · behavioral researcher
The AI-driven cancer cure narrative is finally getting some much-needed scrutiny. While Vivodyne's innovative approach using modular robotic labs and real-world human tissue data is certainly promising, it's essential to acknowledge that even this progress will be incremental. The pharmaceutical industry's 90% failure rate in translating animal trials to human approval suggests that the problem isn't just AI's lack of sophistication – but our fundamental understanding of how biology translates into efficacy. Until we can reconcile these discrepancies, AI-powered cancer cures remain a distant fantasy, not a reality within reach.